Search results
2 wrz 2010 · Because the elimination half-life of memantine is approximately 70 hours, steady state is reached after 2 weeks. As steady state is approached, the difference in peak plasma concentrations between 20 mg once-a-day and 10 mg twice-a-day dosing diminishes (Figure 1).
17 lut 2015 · Memantine has a long elimination half-life of approximately 70 hours, which results in little peak-to-trough concentration variations between doses at steady state (after 2 weeks of therapy). 2, 6 - 8 The soon-to-be-discontinued memantine tablets have been given once daily, which can promote medication adherence and appears to be well tolerated....
2 wrz 2010 · The relatively long plasma elimination half‐life of this drug suggests that once‐daily dosing may be comparable with the current twice‐daily practice. We offer a pharmacokinetic rationale for once‐daily prescribing and suggest that the once‐daily strategy may be comparable to traditional twice‐daily dosing and improve adherence. METHODS.
24 lip 2023 · Estimates of the elimination half-life of amiodarone vary, depending on how the half-life has been measured and the route of amiodarone administration. After long-term oral therapy, amiodarone has a true elimination half-life between 60 and 142 days [ 2,3 ].
31 sty 2024 · The elimination half-life is about 60 to 80 hours. Approximately 48% of the drug administered is eliminated unchanged in the urine. The remaining portion is transformed into 3 polar metabolites with minimal NMDAR antagonistic activity.
Half-life. The terminal elimination half-life of memantine ranges from 60 to 80 hours in humans. 8,12. Following administration of a single oral dose of 10 mg/kg memantine in rats, the elimination half-life was 2.36 ± 0.20 hours. Following a single intravenous dose of 2 mg/kg in rats, the elimination half-life was 2.28 ± 0.48 hours. 7. Clearance
17 lut 2020 · Mean AUC 0-∞ increased by 4%, 60%, and 115% in patients with mild, moderate, and severe renal impairment, respectively. The terminal elimination half-life increased by 18%, 41%, and 95% in patients with mild, moderate, and severe renal impairment, respectively.
